Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy
- PMID: 19683298
- DOI: 10.1016/j.juro.2009.06.023
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy
Abstract
Purpose: Urinary disturbances are common in patients with Parkinson's disease and multiple system atrophy. We investigated the effectiveness and safety of botulinum toxin type A injected into the detrusor muscle in patients with Parkinson's disease and multiple system atrophy who had refractory overactive bladder symptoms and detrusor overactivity.
Materials and methods: All participants underwent clinical and urodynamic assessment, and completed a quality of life questionnaire before botulinum toxin type A treatment, and 1 and 3 months thereafter. Four patients with Parkinson's disease and 2 with multiple system atrophy were enrolled in the study. All patients received 200 U botulinum toxin type A injected into the detrusor muscle at 20 sites under cystoscopic guidance at a single session on an inpatient basis. Outcome measures were clinical assessment (a voiding diary including daytime and nighttime urinary frequency, and episodes of urgency and urge urinary incontinence), urodynamic assessment (including first volume and maximum pressure of uninhibited detrusor contractions, and maximum cystometric capacity) and pressure flow studies.
Results: One and 3 months after botulinum toxin type A injection all patients reported that daytime and nighttime urinary frequency had decreased and quality of life scores improved. No patients had further episodes of urgency and urge urinary incontinence during the 5-month followup. Urodynamics showed improvement in all urinary function variables tested. No systemic side effects were recorded during or after treatment. In all patients post-void urinary residual volume increased and intermittent catheterization was required only in those with multiple system atrophy.
Conclusions: The new beneficial effect that we report in a small study sample encourages larger trials to confirm botulinum toxin type A injection into the detrusor muscle as an effective and safe treatment for refractory overactive bladder symptoms and detrusor overactivity related to Parkinson's disease and multiple system atrophy.
Similar articles
-
Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder.J Urol. 2011 Sep;186(3):960-4. doi: 10.1016/j.juro.2011.04.071. Epub 2011 Jul 24. J Urol. 2011. PMID: 21791351
-
Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.J Urol. 2007 Jun;177(6):2231-6. doi: 10.1016/j.juro.2007.01.130. J Urol. 2007. PMID: 17509328 Clinical Trial.
-
Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.Urology. 2005 Jan;65(1):37-41. doi: 10.1016/j.urology.2004.08.016. Urology. 2005. PMID: 15667859
-
Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.BJU Int. 2008 Jul 25;102 Suppl 1:2-6. doi: 10.1111/j.1464-410X.2008.07820.x. BJU Int. 2008. PMID: 18665971 Review.
-
Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.BJU Int. 2008 Jul 25;102 Suppl 1:7-10. doi: 10.1111/j.1464-410X.2008.07827.x. BJU Int. 2008. PMID: 18665972 Review.
Cited by
-
Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism.CNS Drugs. 2018 Sep;32(9):827-837. doi: 10.1007/s40263-018-0551-3. CNS Drugs. 2018. PMID: 30051337 Review.
-
Bladder Dysfunction in Older Adults: The Botulinum Toxin Option.Drugs Aging. 2022 Jun;39(6):401-416. doi: 10.1007/s40266-022-00950-1. Epub 2022 Jun 13. Drugs Aging. 2022. PMID: 35696022 Review.
-
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.Mov Disord. 2018 Mar;33(3):372-390. doi: 10.1002/mds.27344. Mov Disord. 2018. PMID: 29508455 Free PMC article. Review.
-
Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.J Neurol. 2025 Jan 3;272(1):90. doi: 10.1007/s00415-024-12730-5. J Neurol. 2025. PMID: 39751950 Free PMC article. Review.
-
Current Management and Emerging Therapies in Multiple System Atrophy.Neurotherapeutics. 2020 Oct;17(4):1582-1602. doi: 10.1007/s13311-020-00890-x. Neurotherapeutics. 2020. PMID: 32767032 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical